Publications
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Clinical trial results for TIL therapy in melanoma. Mentions using 'gas-permeable bags or GRex ' for the Rapid Expansion Procedure (REP). Notes that G-Rex allow large-scale expansion to treatment levels (10^10 - 10^11 cells)
Publications
Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease
Describes a protocol for expanding nTregs using G-Rex10 and G-Rex100 devices. The method yielded >10^9 Tregs in 21 days with high purity and suppressive function. G-Rex promoted robust expansion (over 600-fold) compared to 24-well plates (5-6 fold) and maintained telomere length
Publications
SOP: D03.31.22 INITIATION OF EBV- OR ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL)
SOP for initiating CTLs. Describes initiating cells in '24-well plate or GRex40 '. Details seeding 1x10^7 cells in 5mL for G-Rex40 and culturing for 9 days for initial stimulation
Publications
SOP: D03.32.21 EXPANSION OF EBV- OR ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL)
SOP for expanding CTLs. Detailed instructions for using G-Rex40 and G-Rex500. Describes transfer of cells to G-Rex, adding media and IL-2, feeding schedules (removing half media), and splitting cells if density is high
Publications
SOP: D03.05.22 CHARACTERIZATION AND FREEZING OF CYTOTOXIC T-LYMPHOCYTES
SOP for freezing CTLs. Mentions harvesting CTLs from 'wells or GRex '. Provides a protocol for ensuring cell quality and viability during cryopreservation
Publications
SOP: D03.14.23 ADENOVIRUS TRANSDUCTION OF B95-8+ LCL FOR CTL STIMULATION
SOP for transducing LCLs with adenovirus vectors. G-Rex is not explicitly referenced in this document, though it is part of a larger G-Rex workflow for CTL production
Publications
SOP: D03.01.23 GENERATION OF EBV-TRANSFORMED CELL LINES (LYMPHOBLASTOID CELL LINES - LCL)
SOP for generating LCLs. Mentions expansion of LCLs in ' (G40 and G500)' (G-Rex) if large numbers are required. Describes seeding densities and media volumes for G-Rex40 (30 mL) and G-Rex500 (100-200 mL)
Publications
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Describes a static culture protocol for expanding NK cells using K562-mb15-41BBL feeder cells in G-Rex devices. The G-Rex system yielded higher fold expansion (>100-fold) and total cell numbers compared to gas-permeable bags, with no feeding required during the 8-10 day culture period
Publications
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
Details the GMP manufacturing process for trivirus-specific CTLs (CMV, EBV, Adv). The protocol allows for stimulation and expansion in either 24-well plates or G-Rex devices (specifically G-Rex40 and G-Rex500). G-Rex is noted for supporting high-density cell growth and simplifying the process
Publications
Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections
Describes a rapid method (10 days) to generate multivirus-specific CTLs using pepmixes and IL4/IL7. The method uses the G-Rex10 device for stimulation and expansion, allowing the production of large numbers (1x10^8) of virus-specific T cells from a small starting number of PBMCs with minimal manipulation
Publications
Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable to Numbers Needed for Patient Treatment
Details a simplified TIL production method using G-Rex. G-Rex10 is used for initial culture from tumor fragments/digests, and G-Rex100 for rapid expansion (REP). This method reduces media use by 3-4 times and requires fewer vessels and labor compared to traditional 24-well plates and bags
Publications
Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
Describes generating CTL lines targeting multiple tumor-associated antigens (SSX2, MAGEA4, Survivin, etc.) for lymphoma. Uses optimized cytokine cocktails (IL-7, IL-12, IL-15, IL-6/IL-27) for activation. While not explicitly detailed in the excerpts, G-Rex is standard for this group's expansion protocols